Skip to main navigation Skip to search Skip to main content

Common variable immunodeficiency, immune thrombocytopenia, rituximab and splenectomy: important considerations

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Common variable immunodeficiency (CVID) is readily considered in patients presenting with recurrent sino-pulmonary infections, however this disease has a broad range of clinical manifestations and diagnosis can be delayed by several years. We present the case of a 44-year-old postpartum female who presented with nausea, vomiting and abdominal distension. Four years prior, she was hospitalized for treatment of immune thrombocytopenia (ITP) with splenectomy and rituximab followed by two episodes of bacterial meningitis despite immunizations. The recurrent meningitis had been attributed to splenectomy and immunotherapy. During this hospitalization, extensive workup for gastrointestinal pathology was negative and she was diagnosed with intestinal pseudo-obstruction. Her hospital course was complicated by development of severe pseudomonas pneumonia, and subsequent immunoglobulin testing and impaired antibody response to vaccines were consistent with CVID. We review the clinical presentation of CVID, its association with autoimmune disease, and treatment implications, specifically the impact of rituximab therapy and splenectomy on immunoglobulin function and risk of serious infection. Intestinal pseudo-obstruction has been reported in children with CVID, but literature search failed to reveal similar presentation in adults. Physicians must consider the heterogeneous clinical manifestations of CVID to avoid delay in diagnosis and treatment. Institution of appropriate therapy with immunoglobulin replacement is important to decrease risk of serious infection.

Original languageEnglish
Pages (from-to)567-572
Number of pages6
JournalPostgraduate Medicine
Volume128
Issue number6
DOIs
StatePublished - Aug 17 2016

Bibliographical note

Publisher Copyright:
© 2016 Informa UK Limited, trading as Taylor & Francis Group.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Common variable immunodeficiency
  • immune thrombocytopenia
  • intestinal pseudo-obstruction
  • rituximab

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Common variable immunodeficiency, immune thrombocytopenia, rituximab and splenectomy: important considerations'. Together they form a unique fingerprint.

Cite this